Skip to main content
. Author manuscript; available in PMC: 2022 Apr 11.
Published in final edited form as: Ann Breast Surg. 2021 Sep 30;5:30. doi: 10.21037/abs-20-96

Table 4.

Summary of global regulatory agency risk estimates of BIA-ALCL

Country Source Risk
Australia Australian Therapeutic Good Administration 1:2,500–1:25,000 patients
Canada Health Canada Overall: 1:24,177; 1:3,565 (Allergan); 1:16,703 (Mentor)
United Kingdom Medicines and Healthcare Products Regulatory Agency 1:24,000 (implants)
United States Food and Drug Administration 1:3,817–1:30,000

BIA-ALCL, breast implant-associated anaplastic large cell lymphoma.